PHASE I DOSE ESCALATION STUDY OF AUTOLOGOUS TUMOR LYSATE-PULSED DENDRITIC CEL

自体肿瘤裂解物脉冲树突状细胞的 I 期剂量递增研究

• 批准号: 7717994
• 负责人: Joseph A Lasky
• 金额: $ 0.29万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-12-01 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7717994
• 关键词: Autologous; Autologous Dendritic Cells; Childhood; Childhood Brain Neoplasm; Coculture Techniques; Computer Retrieval of Information on Scientific Projects Database; Dendritic Cells; Dose; Dose-Limiting; Funding; Grant; Harvest; Immune response; Institution; Malignant Glioma; Maximum Tolerated Dose; Monitor; Operative Surgical Procedures; Patients; Phase; Physiologic pulse; Pulse taking; Research; Research Personnel; Resources; Scheme; Source; Tissues; Toxic effect; United States National Institutes of Health; intradermal injection; peripheral blood; tumor; tumor progression

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of the study is: To determine if Dose Limiting Toxicity (DLT) is reached in the dose escalation scheme described, using intradermal injections of autologous dendritic cells harvested from peripheral blood precursors and pulsed (co-cultured) with tumor lysate taken from surgical tissues in pediatric patients with malignant gliomas. If DLT is reached, then Maximum tolerated Dose (MTD) will be defined. Secondary objectives of this study are: To monitor survival, tumor progression and cellular immune responses in pediatric brain tumor patients injected with tumor lysate-pulsed dendritic cells.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 该研究的主要目的是： 为了确定在描述的剂量升级方案中是否达到了剂量限制毒性（DLT），使用从外周血液前体中收获的自体树突状细胞的皮内注射，并与从事恶性胶体瘤的儿科患者中从外科手术组织中取出的肿瘤裂解物（共培养）（共培养）（共培养）。 如果达到DLT，则将定义最大耐受剂量（MTD）。 这项研究的次要目标是： 为了监测生存率，注射肿瘤裂解型脉冲的树突状细胞的小儿脑肿瘤患者的肿瘤进展和细胞免疫反应。